Browse By:


    Anti-Malaria Drugs Have Shown Promise in Treating Cancer, and Now Researchers Know Why

    November 15, 2018
    Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson Cancer Center of the University of Pennsylvania say they have identified that target – an enzyme called PPT1 – opening up a new pathway for potential cancer treatments.
  • CAR T

    Abramson Cancer Center Receives $10.7 Million to Study CAR T Cells in Solid Tumors

    October 22, 2018
    A new program project grant from the National Cancer Institute (NCI) will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor (CAR) T cell therapy at fighting solid tumors.
  • Tests

    Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone

    October 11, 2018
    In one of the largest clinical studies to ever examine the impact of using a blood test to detect treatable mutations in non-small cell lung cancer (NSCLC), researchers from the Abramson Cancer Center of the University of Pennsylvania found that they could identify significantly more mutations through liquid biopsy instead of a solid tissue biopsy alone.
  • Oncolink

    Penn Medicine’s OncoLink Receives 2018 CPEN Excellence in Patient Education Award

    October 10, 2018
    The Cancer Patient Education Network (CPEN) honored the Patient Education Team from Penn Medicine’s OncoLink with the 2018 Excellence in Patient Education Award. The award recognizes individuals or programs that use creative approaches to develop and circulate cancer education to patients and health care professionals. The OncoLink team received the award Friday during the CPEN annual meeting in Atlanta.
  • CART

    Penn Discovers New, Rare Mechanism for ALL to Relapse after CAR T Cell Therapy

    October 01, 2018
    A single leukemia cell, unknowingly engineered with the leukemia-targeting chimeric antigen receptor (CAR) lentivirus and infused back into a patient, was able to reproduce and cause a deadly recurrence of pediatric B-cell acute lymphoblastic leukemia (ALL).
  • HPV

    DNA Vaccine Leads to Immune Responses in HPV-Related Head and Neck Cancer

    September 21, 2018
    A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of Pennsylvania tested the immunotherapy approach in two groups of patients with advanced head and neck squamous cell carcinoma (HNSCCa) and found 86 percent showed elevated T cell activity. It is also the first study to show that the vaccine can help immune cells infiltrate tumors.
  • Brain Tissue

    Additional Inhibitor Can Help Anti-VEGF Therapy Overcome Resistance in Deadly Brain Cancer

    August 27, 2018
    Adding another inhibitor to therapies that cut off a tumor’s access to blood vessels could be the key to helping those therapies overcome resistance in glioblastoma, a deadly form of brain cancer.
  • Flash Mob

    CAR T Cell Therapy Receives Approval for Use Across European Union

    August 27, 2018
    The European Commission (EC) has approved a personalized cellular therapy developed at the University of Pennsylvania’s Abramson Cancer Center, making it the first chimeric antigen receptor (CAR) T cell therapy permitted for use in the European Union in two distinct indications.
  • Penn Medicine’s Carl June Receives 2018 Albany Prize

    August 15, 2018
    Albany Medical Center has given out the $500,000 award annually since 2001 to those “who have altered the course of medical research” and is one of the largest prizes in medicine and science in the United States, according to the organization.
  • Release

    Cancer Cells Send Out “Drones” to Battle Immune System from Afar

    August 08, 2018
    The research offers a paradigm-shifting picture of how cancers take a systemic approach to suppressing the immune system. In addition, it also points to a new way to predict which cancer patients will respond to anti-PD1 therapy that disrupts immune suppression to fight tumors and a means of tracking the effectiveness of such therapies.
Share This Page: